Compare Abbott India with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs CIPLA - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA CIPLA ABBOTT INDIA/
CIPLA
 
P/E (TTM) x 47.0 23.3 201.5% View Chart
P/BV x 13.5 2.4 565.1% View Chart
Dividend Yield % 0.5 0.7 75.9%  

Financials

 ABBOTT INDIA   CIPLA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
CIPLA
Mar-19
ABBOTT INDIA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs6,110678 901.2%   
Low Rs3,996484 826.0%   
Sales per share (Unadj.) Rs1,552.2198.2 783.1%  
Earnings per share (Unadj.) Rs188.818.5 1,019.3%  
Cash flow per share (Unadj.) Rs196.435.0 561.4%  
Dividends per share (Unadj.) Rs55.003.00 1,833.3%  
Dividend yield (eoy) %1.10.5 210.8%  
Book value per share (Unadj.) Rs796.6186.3 427.5%  
Shares outstanding (eoy) m21.25805.70 2.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.32.9 111.1%   
Avg P/E ratio x26.831.4 85.3%  
P/CF ratio (eoy) x25.716.6 154.9%  
Price / Book Value ratio x6.33.1 203.5%  
Dividend payout %29.116.2 179.9%   
Avg Mkt Cap Rs m107,376468,031 22.9%   
No. of employees `0003.322.6 14.7%   
Total wages/salary Rs m3,93728,565 13.8%   
Avg. sales/employee Rs Th9,929.37,053.1 140.8%   
Avg. wages/employee Rs Th1,185.11,261.5 93.9%   
Avg. net profit/employee Rs Th1,207.7659.1 183.2%   
INCOME DATA
Net Sales Rs m32,985159,710 20.7%  
Other income Rs m1,1704,766 24.5%   
Total revenues Rs m34,155164,475 20.8%   
Gross profit Rs m5,24530,973 16.9%  
Depreciation Rs m16213,263 1.2%   
Interest Rs m381,684 2.3%   
Profit before tax Rs m6,21520,791 29.9%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2035,695 38.7%   
Profit after tax Rs m4,01214,924 26.9%  
Gross profit margin %15.919.4 82.0%  
Effective tax rate %35.427.4 129.4%   
Net profit margin %12.29.3 130.2%  
BALANCE SHEET DATA
Current assets Rs m22,655124,266 18.2%   
Current liabilities Rs m6,68137,715 17.7%   
Net working cap to sales %48.454.2 89.4%  
Current ratio x3.43.3 102.9%  
Inventory Days Days6591 71.5%  
Debtors Days Days2995 30.7%  
Net fixed assets Rs m835105,190 0.8%   
Share capital Rs m2131,611 13.2%   
"Free" reserves Rs m16,715148,511 11.3%   
Net worth Rs m16,928150,123 11.3%   
Long term debt Rs m038,301 0.0%   
Total assets Rs m24,162239,633 10.1%  
Interest coverage x163.713.3 1,226.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.7 204.8%   
Return on assets %16.86.9 241.9%  
Return on equity %23.79.9 238.4%  
Return on capital %36.911.8 312.1%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36957,410 0.6%   
Fx outflow Rs m3,80719,041 20.0%   
Net fx Rs m-3,43838,368 -9.0%   
CASH FLOW
From Operations Rs m1,52716,911 9.0%  
From Investments Rs m-2,148-16,687 12.9%  
From Financial Activity Rs m-1,024-3,487 29.4%  
Net Cashflow Rs m-1,646-3,451 47.7%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 7.9 12.2 64.8%  
FIIs % 0.1 23.7 0.4%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.1 26.2 65.3%  
Shareholders   18,270 161,166 11.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   GSK PHARMA  NATCO PHARMA  ORCHID PHARMA LTD  AJANTA PHARMA  FULFORD INDIA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS